Yogesh Mannalal Agrawal
Fortune : 654 M $ au 30/06/2026
Fortune : 654 M $ au 30/06/2026
Yogesh Mannalal Agrawal currently works at Ajanta Pharma Ltd., as Joint Managing Director & Executive Director, Ajanta Pharma (USA), Inc., as Director, Ajanta Pharma (Mauritius) Ltd., as Director, Gabs Investments Pvt Ltd., as Director, Ajanta Pharma Philippines, Inc., as Director, Ajanta Pharma UK Ltd., as Director, Inspira Martifer Solar Ltd., as Director, Ajanta Pharma Mauritius (International) Ltd., as Director, and Yogesh Agrawal Trust, as Trustee.
Mr. Agrawal received his undergraduate degree from Johnson & Wales University, Inc.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
AJANTA PHARMA LIMITED 14,47% | 09/07/2026 | 18 078 147 ( 14,47% ) | 654 M $ | 30/06/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| AJANTA PHARMA LIMITED | Directeur Général | 21/12/2009 |
Ajanta Pharma (Mauritius) Ltd.
Ajanta Pharma (Mauritius) Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical dosages | Directeur/Membre du Conseil | - |
Ajanta Pharma UK Ltd. | Directeur/Membre du Conseil | - |
Inspira Martifer Solar Ltd. | Directeur/Membre du Conseil | - |
Ajanta Pharma (USA), Inc.
Ajanta Pharma (USA), Inc. Pharmaceuticals: MajorHealth Technology Manufactures capsules and tablets | Directeur/Membre du Conseil | - |
Ajanta Pharma Philippines, Inc.
Ajanta Pharma Philippines, Inc. Part of Ajanta Pharma Ltd., Ajanta Pharma Philippines, Inc. is a wholly owned subsidiary of a pharmaceutical supplier specializing in first-to-market pharmaceutical compounds, unique therapeutically optimized combinations, and value-branded equivalents. The company is located in the Philippines. The Filipino company offers a diverse portfolio targeting various conditions including type 2 diabetes, hypertension, allergic rhinitis, COPD, benign prostatic hyperplasia, vertigo, and hyperuricemia in chronic kidney disease. Key products include Asenza Plus (a combination of pioglitazone hydrochloride and glimepiride for improved glycemic control in type 2 diabetes), Maxivent (doxofylline for bronchial asthma and COPD), Nebiloc CCB (nebivolol hydrochloride and amlodipine besilate for essential hypertension and chronic stable angina), and Co-Altria (montelukast sodium and levocetirizine dihydrochloride for allergic rhinitis). Additional products include fixed dose combinations for diabetes and cholesterol management, as well as treatments for benign prostatic hyperplasia and other conditions. Ajanta Pharma Philippines also provides patient education resources, career opportunities, and publishes articles on pharmaceutical developments and treatments. The company's products are prescription-based and come with detailed prescribing information. | Directeur/Membre du Conseil | - |
Ajanta Pharma Mauritius (International) Ltd. | Directeur/Membre du Conseil | - |
Gabs Investments Pvt Ltd.
Gabs Investments Pvt Ltd. Financial ConglomeratesFinance Provides investment services | Directeur/Membre du Conseil | - |
Yogesh Agrawal Trust
Yogesh Agrawal Trust Investment Trusts/Mutual FundsMiscellaneous Provides trust services | Directeur/Membre du Conseil | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 10 |
|---|---|
Ajanta Pharma Ltd.
Ajanta Pharma Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals products | Health Technology |
Johnson & Wales University, Inc.
Johnson & Wales University, Inc. Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ajanta Pharma (USA), Inc.
Ajanta Pharma (USA), Inc. Pharmaceuticals: MajorHealth Technology Manufactures capsules and tablets | Health Technology |
Ajanta Pharma (Mauritius) Ltd.
Ajanta Pharma (Mauritius) Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical dosages | Health Technology |
Gabs Investments Pvt Ltd.
Gabs Investments Pvt Ltd. Financial ConglomeratesFinance Provides investment services | Finance |
Ajanta Pharma Philippines, Inc.
Ajanta Pharma Philippines, Inc. Part of Ajanta Pharma Ltd., Ajanta Pharma Philippines, Inc. is a wholly owned subsidiary of a pharmaceutical supplier specializing in first-to-market pharmaceutical compounds, unique therapeutically optimized combinations, and value-branded equivalents. The company is located in the Philippines. The Filipino company offers a diverse portfolio targeting various conditions including type 2 diabetes, hypertension, allergic rhinitis, COPD, benign prostatic hyperplasia, vertigo, and hyperuricemia in chronic kidney disease. Key products include Asenza Plus (a combination of pioglitazone hydrochloride and glimepiride for improved glycemic control in type 2 diabetes), Maxivent (doxofylline for bronchial asthma and COPD), Nebiloc CCB (nebivolol hydrochloride and amlodipine besilate for essential hypertension and chronic stable angina), and Co-Altria (montelukast sodium and levocetirizine dihydrochloride for allergic rhinitis). Additional products include fixed dose combinations for diabetes and cholesterol management, as well as treatments for benign prostatic hyperplasia and other conditions. Ajanta Pharma Philippines also provides patient education resources, career opportunities, and publishes articles on pharmaceutical developments and treatments. The company's products are prescription-based and come with detailed prescribing information. | |
Ajanta Pharma UK Ltd. | |
Inspira Martifer Solar Ltd. | |
Ajanta Pharma Mauritius (International) Ltd. | |
Yogesh Agrawal Trust
Yogesh Agrawal Trust Investment Trusts/Mutual FundsMiscellaneous Provides trust services | Miscellaneous |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national